Skip to main content
. Author manuscript; available in PMC: 2012 Nov 15.
Published in final edited form as: Clin Cancer Res. 2011 Aug 15;17(22):7080–7092. doi: 10.1158/1078-0432.CCR-11-0098

Figure 3. Treatment of melanoma cells with three different inhibitors.

Figure 3

MTT assays of C8161 (3A, B-RAF and N-RAS wild type), UACC903 (3B, B-RAFV600E) and 1205Lu, (3C, B-RAFV600E) melanoma cells treated with different concentrations of Riluzole, Sorafenib, PLX4720 or the combination of the compounds at half of the concentration of each one alone. NT - No treatment; DMSO - Vehicle only treatment: Riluzole (Ril); Sorafenib (Sor); PLX4720 (PLX).